NextGen Immuno Therapeutics

About Us

NextGen Immuno Therapeutics is a HealthTech company - building the future of immune diagnostics through AiResolve - an AI-powered, scalable SaaS platform for precision medicine. Designed for early detection and personalized treatment of immune diseases like cancer, autoimmune and Graft-versus-host disease (GVHD). AiResolve integrates multimodal biological and clinical data with explainable AI. It enables hospitals to predict complications before symptoms appear—reducing mortality by up to 30%, shortening hospital stays threefold, and cutting treatment costs by over 50%. For pharma and research, it accelerates biomarker discovery, clinical trial stratification, and drug repositioning. AiResolve is secure, GDPR-compliant, and seamlessly integrates with existing hospital IT systems.

Our Solution: AiResolve

Multimodal data Integration

Combines Multimodal data with clinical data to deliver high-resolution, actionable insights.

Early Detection

AiResolve Early Detection empowers clinicians to identify immune related diseases at the pre-symptomatic stage, enabling timely intervention and personalized treatment. This leads to significantly improved survival rates, reduced treatment time, and lower healthcare costs.

Biomarker Discovery

AiResolve’s biomarker discovery for cancer, autoimmune and Graft-versus-host disease (GVHD) uses multi-omics and explainable AI to detect early immune dysregulation—such as T cell activation, Treg imbalance, and APC dysfunction—after transplant. This enables early risk prediction, patient stratification, and timely interventions to improve outcomes and reduce complications.

Patient stratification

AiResolve uses multimodal data with clinical data and explainable AI to identify molecular fingerprints that distinguish high-risk vs. low-risk patients, responders vs. non-responders, or early vs. advanced disease stages.

Additional Treatment Discovery

AiResolve accelerates additional treatment discovery to reveal hidden therapeutic opportunities. The platform identifies drug repurposing candidates, discovers synergistic drug combinations, and provides insights into patient-specific therapy responses. By mapping immune dysfunction and tumor escape pathways, AiResolve not only uncovers new treatment options but also helps refine existing ones, enabling personalized, cost-effective, and faster-to-market solutions for cancer, autoimmune disorders, and transplant-related complications.

GDPR/MDR Compliant

Ensures data privacy, regulatory alignment, and seamless clinical integration across hospital systems.

Our Team

AiResolve is led by a world-class team of scientists, clinicians, and entrepreneurs with expertise in computational biology, immunology, clinical dermatology, and biotech strategy. Together, we bridge science and business to bring transformative diagnostics to patients worldwide.

Dr. Ram Vinay Pandey, PhD

Founder & CEO

Dr. Hanna Knaus, M.D., Ph.D.

Clinical Lead & GVHD expert

Dr. Lusia Unterluggauer

Clinical Scientist

Dr. Anand Kant Das, PhD

Business Lead, Abu Dhabi, UAE

Prof. George Stary, MD, PhD

Co-founder & CSO

Jaishree Singh

CIO & AI/ML Expert, Vienna

Dr. Rabindranath Paul, PhD

Scientific Lead, Abu Dhabi, UAE

Dr. Arunima Chaudhari, PhD

Cancer Immunologist, Lund, Sweden

Dr. Priyanka Dutta Passecker, MBA, PhD

Business Development Expert

Juraj Hunák, MSc (WU)

Chief Financial Officer (CFO)

Laura Maria Gail

Immunologist

Nishant Kumar Verma

CTO & AI/ML Expert, Vienna

Advisory Board

From Vision to Validation—Strategic Guidance Backed by Decades of Success

Prof. Werner Rabitsch

Stem Cell Transplant Expert

Prof. Yenan Bryceson

Cancer Immunologist

Dr. André Rendeiro

Computational Biology/AI Expert

Prof. Robert Zeiser

Hematologist, Oncologist

Prof. Hildegard Greinix

GVHD Expert

Dr. Andreas Weinhäusel

Molecular Diagnostics Expert

Dr. Marc J. Brehme, MBA

Strategy & Fundraising Advisor

Florian Glatt-Wodzyński

Business & Regulatory Advisor

Martin Rudolf, BS IBA

Business Development Advisor

Our Strategic Partners

Collaborating with world-renowned institutions to advance precision medicine and transform healthcare.

Medical University of Vienna | Visit Website →

One of Europe's leading academic health centers, closely affiliated with Vienna General Hospital (AKH Wien) for access to highly specialized departments and digitalized clinical environments.

Practical validation of hospital IT integration
Standards-driven evolution of the MVP
Early clinical feedback to increase market readiness

Medical University of Graz | Visit Website →

A leading hub for biomedical research and digital health in Central Europe, integrated with LKH-Univ. Klinikum Graz for system-level testing and validation.

Access to structured clinical datasets
Real-world validation insights
Strengthened credibility with stakeholders

Karolinska Institutet, Stockholm | Visit Website →

A global pioneer in translational medicine and digital health innovation, bridging cutting-edge clinical research with large-scale deployment of AI and healthcare technologies.

Trusted medical data standards (e.g., SNOMED CT, FHIR)
Early validation in real-world clinical settings
International credibility and recognition

CeMM Research Centre | Visit Website →

CeMM is a leading European institute at the intersection of biomedicine, systems biology, and precision medicine — embedded within the clinical ecosystem of Vienna General Hospital (AKH).

Austrian Institute of Technology (AIT) | Visit Website →

Austria's premier applied research center for digital health and clinical decision support — supporting MDR/EU AI Act alignment, clinical algorithms, and real-world deployment.

Prognica Labs | Visit Website →

Accelerating drug discovery from molecule to medicine through autonomous AI agents and computational platforms.

10× faster discovery via AI automation
Lower early-stage costs through in-silico evaluation
Reduced clinical risk using digital twin simulations

Publications

Our team has published extensively in top-tier journals such as Science, Immunity, and Journal of Experimental Medicine, advancing the fields of computational immunology, Oncology, GVHD research, and precision diagnostics.

Strobl J, Gail LM, Krecu L, Madad S, Kleissl L, Unterluggauer L, Redl A, Brazdilova K, Saluzzo S, Wohlfarth P, Knaus HA, Mitterbauer M, Rabitsch W, Haniffa M, Stary G. Diverse macrophage populations contribute to distinct manifestations of human cutaneous graft-versus-host disease. Br J Dermatol. 2024 Feb 16;190(3):402-414.
DOI: 10.1093/bjd/ljad402 | PMID: 38010706 | PMCID: PMC10873647.

Pandey RV, Strobl J, Redl A, Unterluggauer L, Gail L, Kleissl L, Müller S, Atzmüller D, Fife-Gernedl V, Krausgruber T, Knaus H, Mitterbauer M, Wohlfarth P, Rabitsch W, Bock C, Stary G. Epigenetic regulation of T cell lineages in skin and blood following hematopoietic stem cell transplantation. Clin Immunol. 2023 Mar;248:109245.
DOI: 10.1016/j.clim.2023.109245 | PMID: 36702179.

Strobl J, Gail LM, Kleissl L, Pandey RV, Smejkal V, Huber J, Puxkandl V, Unterluggauer L, Dingelmaier-Hovorka R, Atzmüller D, Krausgruber T, Bock C, Wohlfarth P, Rabitsch W, Stary G. Human resident memory T cells exit the skin and mediate systemic Th2-driven inflammation. J Exp Med. 2021 Nov 1;218(11):e20210417.
DOI: 10.1084/jem.20210417 | PMID: 34643646 | PMCID: PMC8563284.

Strobl J, Pandey RV, Krausgruber T, Bayer N, Kleissl L, Reininger B, Vieyra-Garcia P, Wolf P, Jentus MM, Mitterbauer M, Wohlfarth P, Rabitsch W, Stingl G, Bock C, Stary G. Long-term skin-resident memory T cells proliferate in situ and are involved in human graft-versus-host disease. Sci Transl Med. 2020 Nov 18;12(570):eabb7028.
DOI: 10.1126/scitranslmed.abb7028 | PMID: 33208504 | PMCID: PMC7615006.

Strobl J, Pandey RV, Krausgruber T, Kleissl L, Reininger B, Herac M, Bayer N, Krall C, Wohlfarth P, Mitterbauer M, Kalhs P, Rabitsch W, Bock C, Hopfinger G, Stary G. Anti-Apoptotic Molecule BCL2 Is a Therapeutic Target in Steroid-Refractory Graft-Versus-Host Disease. J Invest Dermatol. 2020 Nov;140(11):2188-2198.
DOI: 10.1016/j.jid.2020.02.029 | PMID: 32247860.

Lim CX, Redl A, Kleissl L, Pandey RV, Mayerhofer C, El Jammal T, Mazic M, Gonzales K, Sukhbaatar N, Krausgruber T, Bock C, Hengstschläger M, Calender A, Pacheco Y, Stary G, Weichhart T. Aberrant Lipid Metabolism in Macrophages Is Associated with Granuloma Formation in Sarcoidosis. Am J Respir Crit Care Med. 2024 May 1;209(9):1152-1164.
DOI: 10.1164/rccm.202307-1273OC | PMID: 38353578 | PMCID: PMC7617514.

Zitti B, Hoffer E, Zheng W, Pandey RV, Schlums H, Perinetti Casoni G, Fusi I, Nguyen L, Kärner J, Kokkinou E, Carrasco A, Gahm J, Ehrström M, Happaniemi S, Keita ÅV, Hedin CRH, Mjösberg J, Eidsmo L, Bryceson YT. Human skin-resident CD8+ T cells require RUNX2 and RUNX3 for induction of cytotoxicity and expression of the integrin CD49a. Immunity. 2023 Jun 13;56(6):1285-1302.e7.
DOI: 10.1016/j.immuni.2023.05.003 | PMID: 37269830.

Kokkinou E, Soini T, Pandey RV, van Acker A, Theorell J, Czarnewski P, Kvedaraite E, Vandamme N, Lourda M, Sorini C, Weigel W, Carrasco A, Tibbitt CA, Schlums H, Lindforss U, Nordenvall C, Ljunggren M, Ideström M, Svensson M, Henter JI, Villablanca EJ, Bryceson YT, Rolandsdotter H, Mjösberg J. The single-cell transcriptional landscape of innate and adaptive lymphocytes in pediatric-onset colitis. Cell Rep Med. 2023 May 16;4(5):101038.
DOI: 10.1016/j.xcrm.2023.101038 | PMID: 37160121 | PMCID: PMC10213874.

Stary V, Pandey RV, List J, Kleissl L, Deckert F, Kabiljo J, Laengle J, Gerakopoulos V, Oehler R, Watzke L, Farlik M, Lukowski SW, Vogt AB, Stary G, Stockinger H, Bergmann M, Pilat N. Dysfunctional tumor-infiltrating Vδ1+ T lymphocytes in microsatellite-stable colorectal cancer. Nat Commun. 2024 Aug 13;15(1):6949.
DOI: 10.1038/s41467-024-51025-1 | PMID: 39138181 | PMCID: PMC11322529.